|
 |
Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE* 3Leiden. CETP transgenic mice with or without treatment with atorvastatin
S Khnast, JWA van der Hoorn... - Journal of ..., 2012 - Objective: Aliskiren is the first commercially available, orally active, direct renin inhibitor approved to treat hypertension. The reninangiotensin system has been shown to be a significant contributor to the development of hypercholesterolemia-induced ...
More Details:
Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE* 3Leiden. CETP transgenic mice with or without treatment with atorvastatin |
 |
 |